Desensitization protocol should not be used in acute lymphoblastic leukemia patients with silent inactivation of PEGasparaginase

Por Tong, Wing H., Pieters, Rob, Tissing, Wim J.E., van der Sluis, Inge M.
Publicado em 2014

The toxicity of very prolonged courses of PEGasparaginase or Erwinia asparaginase in relation to asparaginase activity, with a special focus on dyslipidemia

Por Tong, Wing H., Pieters, Rob, de Groot-Kruseman, Hester A., Hop, Wim C. J., Boos, Joachim, Tissing, Wim J. E., van der Sluis, Inge M.
Publicado no Haematologica (2014)

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy

Por Tong, Wing H., van der Sluis, Inge M., Alleman, Cathelijne J.M., van Litsenburg, Raphaële R.L., Kaspers, Gertjan J. L., Pieters, Rob, Uyl-de Groot, Carin A.
Publicado em 2013

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Por Tong, Wing H., Pieters, Rob, Kaspers, Gertjan J. L., te Loo, D. Maroeska W. M., Bierings, Marc B., van den Bos, Cor, Kollen, Wouter J. W., Hop, Wim C. J., Lanvers-Kaminsky, Claudia, Relling, Mary V., Tissing, Wim J. E., van der Sluis, Inge M.
Publicado em 2014